No AccessJournal of UrologyAdult Urology1 Dec 2018

Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment

    View All Author Information


    SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. In this study we sought to characterize the effectiveness of SelectMDx in a population of American men with elevated prostate specific antigen.

    Materials and Methods:

    We developed a Markov decision analytical model to simulate the chain of events and downstream outcomes associated with ultrasound guided prostate biopsy and a strategy in which the biomarker panel is implemented prior to biopsy. The primary outcome was health outcomes, measured in QALYs (quality-adjusted life years). The secondary outcome was health care costs from the Medicare payer perspective. Multiple 1-way sensitivity analyses were performed to characterize model robustness.


    The expected mean QALYs per patient under the current standard was 10.796 at a cost of $11,060 during an 18-year horizon. Incorporating the urinary biomarker panel resulted in an expected mean of 10.841 QALYs per patient and a mean cost of $9,366, representing an average of 0.045 QALYs gained at a cost savings of $1,694 per patient. When extrapolating these data to a conservative estimate of 311,879 men per year undergoing biopsy, one would expect that the biomarker panel would result in an incremental 14,035 QALYs gained at a cost savings of $528,323,026 in each yearly cohort. The biomarker panel strategy dominated the current standard across a wide range of sensitivity analyses.


    Routine use of the SelectMDx urinary biomarker panel to guide biopsy decision making improved health outcomes and lowered costs in American men at risk for prostate cancer. This strategy may optimize the value of prostate cancer risk assessment in an era of increasing financial accountability.


    • 1 : Cancer statistics, 2016. CA Cancer J Clin2016; 66: 7. Google Scholar
    • 2 : Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst2011; 103: 117. Google Scholar
    • 3 : Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score. Eur Urol2006; 49: 49. Google Scholar
    • 4 NCCN Guidelines®: Prostate Cancer, 2012. Available at Accessed July 2, 2018. Google Scholar
    • 5 : Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol2013; 189: S12. LinkGoogle Scholar
    • 6 : Prostate biopsy complications: a dual analysis. Urology2016; 93: 135. Google Scholar
    • 7 : Overdiagnosis and overtreatment of prostate cancer. Eur Urol2014; 65: 1046. Google Scholar
    • 8 : Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med2012; 367: 203. Google Scholar
    • 9 : Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst2009; 101: 374. Google Scholar
    • 10 : Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics2008; 64: 10. Google Scholar
    • 11 : Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol2016; 70: 740. Google Scholar
    • 12 : Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res2015; 21: 3061. Google Scholar
    • 13 NCCN Clinical Practice Guidelines in Oncology: Early Detection of Prostate Cancer, 2016. Available at Accessed October 3, 2017. Google Scholar
    • 14 : AUA Policy Statement on the use of multiparametric magnetic resonance imaging in the diagnosis, staging and management of prostate cancer. J Urol2017; 198: 832. LinkGoogle Scholar
    • 15 : A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol2015; 68: 464. Google Scholar
    • 16 : More judicious use of expectant management for localized prostate cancer during the last 2 decades. J Urol2017; 197: 614. LinkGoogle Scholar
    • 17 : Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med2014; 370: 932. Google Scholar
    • 18 : Decision Modelling for Health Economic Evaluation. New York: Oxford University Press2006. Google Scholar
    • 19 : Quality-of-life effects of prostate-specific antigen screening. N Engl J Med2012; 367: 595. Google Scholar
    • 20 : Impact of prostate-specific antigen (PSA) screening trials and revised PSA screening guidelines on rates of prostate biopsy and postbiopsy complications. Eur Urol2017; 71: 55. Google Scholar
    • 21 : Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med2013; 158: 853. Google Scholar
    • 22 : Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int2013; 111: 437. Google Scholar
    • 23 : National Comparisons of Commercial and Medicare Fee-For-Service Payments to Hospitals. Available at Accessed July 2, 2018. Google Scholar
    • 24 Medicare Payment Advisory Commission: Report to the Congress: Medicare Payment Policy. Available at Accessed July 2, 2018. Google Scholar
    • 25 : Screening for prostate cancer: U. S. Preventive Services Task Force recommendation statement. U. S. Preventive Services Task Force. Ann Intern Med2012; 157: 120. Google Scholar
    • 26 : The US Preventive Services Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA2017; 317: 1949. Google Scholar
    • 27 : Better Care. Smarter Spending. Healthier People: Paying Providers for Value, Not Volume. Available at Accessed July 2, 2018. Google Scholar
    • 28 : Using Medicare prices—toward equity and affordability in the ACA marketplace. N Engl J Med2017; 377: 2309. Google Scholar
    • 29 : MRI-targeted or standard biopsy for prostate cancer diagnosis. N Engl J Med2018; 378: 1767. Google Scholar